Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H24O2 |
Molecular Weight | 272.382 |
Optical Activity | ( + ) |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]3([H])C4=C(CC[C@@]23[H])C=C(O)C=C4
InChI
InChIKey=VOXZDWNPVJITMN-ZBRFXRBCSA-N
InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
Molecular Formula | C18H24O2 |
Molecular Weight | 272.382 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:14:36 UTC 2023
by
admin
on
Fri Dec 15 15:14:36 UTC 2023
|
Record UNII |
4TI98Z838E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
35384-7
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
34290-7
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
34286-5
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
12595-5
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
2239-2
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
WHO-ATC |
G03CA03
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
WHO-VATC |
QG03CA03
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
CFR |
21 CFR 522.840
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
83097-6
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
2240-0
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
14715-7
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
15062-3
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
12214-3
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
34288-1
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
FDA ORPHAN DRUG |
231706
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
WHO-VATC |
QG03CA53
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
25401-1
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
CFR |
21 CFR 310.527
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
WHO-VATC |
QG03AB08
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
NDF-RT |
N0000011402
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
WHO-ATC |
G03AA14
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
13883-4
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
2246-7
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
WHO-VATC |
QG03AA14
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
CFR |
21 CFR 556.240
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
72873-3
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
34287-3
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
55857-7
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
35207-0
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
21263-9
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LIVERTOX |
372
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
2243-4
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
2245-9
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
2238-4
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
31176-1
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
WHO-ATC |
G03CA53
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
WHO-ATC |
G03AB08
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
14960-9
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
2241-8
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
IOA (WITHDRAWN: CONTRACEPTION)
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
NDF-RT |
N0000000100
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
12213-5
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
34291-5
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
CFR |
21 CFR 522.2477
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
NDF-RT |
N0000175825
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
44730-0
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
34289-9
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
CFR |
21 CFR 862.1430
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
CFR |
21 CFR 862.1260
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
NCI_THESAURUS |
C2293
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
13736-4
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
55858-5
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
83096-8
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
2242-6
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
||
|
LOINC |
2244-2
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1013
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
200-023-8
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
ESTRADIOL
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
Estradiol
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
DB00783
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
SUB96040
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
23965
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
m5028
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | Merck Index | ||
|
Estradiol (medication)
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
D004958
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
20293
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
DTXSID0020573
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
406
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
C478
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
CHEMBL135
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
1057
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
50-28-2
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
100000091739
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
9895
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
4TI98Z838E
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
16469
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
1250008
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
SUB07242MIG
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
4TI98Z838E
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
4083
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | RxNorm | ||
|
SUB21195
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
3589
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY | |||
|
5757
Created by
admin on Fri Dec 15 15:14:37 UTC 2023 , Edited by admin on Fri Dec 15 15:14:37 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
SOLVATE->ANHYDROUS | |||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TARGET -> AGONIST |
BINDING
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SUBSTANCE->BASIS OF STRENGTH |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST |
Binding Assay
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT |
E2 is then extensively metabolized to estrone (E1) (15%), estrone sulfate (E1S) (65%), and other compounds.
|
||
|
METABOLITE -> PARENT |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
E2 is then extensively metabolized to estrone (E1) (15%), estrone sulfate (E1S) (65%), and other compounds.
|
||
|
METABOLITE LESS ACTIVE -> PARENT |
IN-VITRO
|
||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT |
IN-VIVO
URINE
|
||
|
PARENT -> METABOLITE |
Metabolite produced by hydrolysis. Estramustine,s primary mechanism of antineoplastic action is inhibition of mitosis.
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
|
||
|
PARENT -> METABOLITE ACTIVE | |||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
IN-VITRO
Scientific Literature
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
PARENT -> IMPURITY |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
ESTRADIOL VALERATE |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
ESTRADIOL VALERATE |
|
||